A Phase III, open-label, multicenter study to evaluate contraceptive efficacy and safety of depot medroxyprogesterone acetate (150 mg/ml) injected subcutaneously every 6 months
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Medroxyprogesterone (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Acronyms DMPA-XT
Most Recent Events
- 16 Jul 2024 Planned End Date changed from 24 Jun 2025 to 15 Jan 2026.
- 06 Jul 2022 Status changed from not yet recruiting to recruiting.
- 30 May 2022 New trial record